What is ABclonal Technology?
ABclonal Technology operates within the life sciences sector, specializing in the provision of research-use biological reagents and associated support services. The company's product portfolio encompasses antibodies, proteins, peptides, assay-related materials, and other molecular biology products designed to enhance research quality and experimental consistency. Its core activities align with chemicals and related products manufacturing, focusing on the production and supply of specialized biological inputs for scientific and laboratory customers. A secondary alignment with research and development is evident through its customized solutions and integration into laboratory research workflows.
How much funding has ABclonal Technology raised?
ABclonal Technology has raised a total of $92.9M across 1 funding round:
Series C
$92.9M
Series C (2021): $92.9M with participation from Kinghall Ventures, Sigma Square Capital, Sequoia Capital China, LYFE Capital, and Lucion Capital
Key Investors in ABclonal Technology
Sigma Square Capital
Sigma Square Capital, established in 2015, focuses on emerging areas including the Internet, consumer upgrades, and healthcare, leveraging in-depth research and first-hand information for its investments.
Sequoia Capital China
Sequoia Capital China is part of a global venture capital firm with a strong track record of partnering with entrepreneurs to create market leaders, investing across venture, growth, and late-stage opportunities.
Kinghall Ventures
Kinghall Ventures is an investor participating in the Series C funding round for ABclonal Technology.
What's next for ABclonal Technology?
The substantial enterprise-level funding, including the recent strategic investment, positions ABclonal Technology for significant expansion and advancement in the competitive life sciences market. This capital infusion is likely to fuel further research and development initiatives, enhance production capabilities, and broaden market reach. The company's focus on critical biological reagents suggests a trajectory aimed at supporting the growing demands of scientific discovery and pharmaceutical innovation. Strategic partnerships and technological advancements are anticipated as the company leverages this financial backing to solidify its market position and explore new avenues for growth.
See full ABclonal Technology company page
